Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CaverStem on Fb—INTERNATIONAL:
Dr. Alex Gershman with guest Dr. Dmitri Pushkar, Professor and Chairman Department of Urology MSMSU, General Scientific Secretary Russian Society of Urology, Urologist General of Russia at AUA conference May 20, 2018.
But MMs don’t control the reporting mechanisms of the brokerages. If so, then we truly have an EPIC dilemma on our hands!
Weird how the line graph doesn’t reflect that
Huh: WHEN did we hit .02 today? Both TDAm and iHub show the days range as .0163-.02, but neither LINE graph shows it reaching that high. What am I missing?
Only serious and sustained to do that, I think, is to get a HUGE number of new buyers. And that comes with publicity, no?
Who controls those price moves after hours?
I’m not validating that low bid, just saying it sets to .0001 and 1.00 after trading. WTH is that all about?
Notice too, on the downside, that the BID is .0001
It’s been doing that every day for over a week
LOW not love
Market clearly in “wait and see” mode. Love volume (11M) with 90 minutes left.
What sorts of things tell you this? Trying to learn here ??
Looks like we bottomed out?
Cool! Where have we been these last 2 trading sessions?
I thought high RSI (over 65) indicated an overbought stock that was due for corrective selling?
That was my thought too—all I hear is naysayers talking about dilution (and 3B shares ARE authorized), but so far we only see about 700M used.
Where can one follow these statistics?
Can anyone find financials for Medistem from around the time they were bought out? I have to believe that info could give a rough baseline of what to expect here—although I sense that CELZ is much farther along developmentally than Medistem was at the time of the buyout.
Are you saying that a reverse split is inevitable? Don’t you think that revenues could realistically grow to such an extent as to support the existing float (or even on as high as 1B shares?
What was your basis for declaring “90% chance that this hits $1”?
I betcha those fools are screaming “911” NOW!
Gotcha. That’s why I set my GTC at $5/share. No way it would every go up so fast that I couldn’t adjust higher before my GTC was eclipsed. Hope springs eternal. Lol
At the agreed upon purchase price per share, right? What else would one expect? I’m lost as to the issue in this discussion. Thank you.
So what would be the impact on shareholders?
Stay surly, my friend!
Other possible manipulator comm signals: recent trades of “66” and “8085”
SADDLE UP!
There’s also one for 1056(0) and 1033(0)
I actually see THREE of them!
What do those numbers represent and where?
I think that their strategy has been to lead with CaverStem, which should generate substantial revenues to satisfy most debt and create a balance sheet that will drive the PPS up. From there, focus on single roll-outs: MUCH easier to manage and convert quickly into market cap than the alternative (trying to be all things to all people right away).
The manipulators are being driven from the temple!
If NAKED shorting is now illegal, why does the SEC not REQUIRE brokers to monitor and PREVENT such trading activity and, more importantly, when can we expect such measures to be in place? FYI “the 9th of Never” is not an acceptable answer.
From your mouth (or fingers, I guess) to God’s ears, SFL!
Last tweet on CaverStem Twitter was Jan 23. Please clarify your reference.
Don’t you think they have a financial plan that will allow them to provide CaverStem kits to physicians right away? Why else would physicians—including world-renowned urologists—risk their professional reputations on something whose sustainability was even the slightest bit in question? Finally, don’t you think you might also want to know the price per kit before you rushed to the conclusion (based on what I have no idea) that the company is cash-starved in a way that will threaten its very viability? Dr. Thomas Ichim’s last venture was purchased for about $1.25/share—and that company was NOWHERE near commercialization, whereas CELZ is NOW—so you’ll have to forgive me for trusting his judgment over yours. I’ll sit back and wait for my payday.